Tadalafil once daily in the treatment of lower urinary tract symptoms ( LUTS ) suggestive of benign prostatic hyperplasia ( BPH ) in men without erectile dysfunction
Open Access
- 23 May 2013
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 112 (7) , 990-997
Abstract
Objectives: To assess the safety and efficacy of tadalafil once daily on lower urinary tract symptoms suggestive of clinical benign prostatic hyperplasia ( BPH‐LUTS ) in men without erectile dysfunction ( ED ). To compare these with effects in men with ED . Patients and Methods: After a 4‐week washout period and 4‐week placebo run‐in period, 1089 men without ED ( n = 338) and with ED ( n = 751) were randomly assigned to placebo or tadalafil 5 mg once daily for 12 weeks in three global clinical studies with similar designs. In the pooled dataset, post hoc analyses of covariance assessed the impact and severity of BPH‐LUTS using the I nternational P rostate S ymptom S core ( IPSS ) and the BPH I mpact I ndex ( BII ) and IPSS quality‐of‐life ( IPSS ‐ QoL ) subscores. Safety was assessed using treatment‐emergent adverse events. The treatment‐by‐ ED ‐status interaction was used to assess efficacy differences between the with/without ED subgroups. Results: Men without ED were similar in BPH‐LUTS severity/previous therapy to men with ED . Tadalafil significantly reduced BPH‐LUTS from baseline when compared with placebo in men without ED ( IPSS −5.4 vs −3.3, P < 0.01; IPSS voiding subscore −3.5 vs −2.0, P < 0.01; IPSS storage subscore −1.9 vs −1.3, P < 0.05). Tadalafil also significantly improved quality of life from baseline when compared with placebo in men without ED ( IPSS ‐ QoL −1.0 vs −0.7, BII −1.4 vs −1.0; both P < 0.05). Between‐ ED ‐subgroup interactions were not significant (all P > 0.68). Tadalafil was safe and well tolerated. Conclusion: Tadalafil 5 mg once daily improved BPH‐LUTS in men without ED by a magnitude similar to that observed in men with ED . The adverse event profile in men without ED was consistent with that observed in men with ED .Keywords
This publication has 25 references indexed in Scilit:
- Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind StudyThe Journal of Sexual Medicine, 2012
- Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of actionNeurourology and Urodynamics, 2011
- Acute Vardenafil Administration Improves Bladder Oxygenation in Spontaneously Hypertensive RatsThe Journal of Sexual Medicine, 2010
- Regular Intercourse Protects Against Erectile Dysfunction: Tampere Aging Male Urologic StudyThe American Journal of Medicine, 2008
- Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2007
- Effects of Acute Treatment With Tamsulosin Versus Alfuzosin on Ejaculatory Function in Normal VolunteersJournal of Urology, 2006
- The International Index of Erectile Function (IIEF): a state-of-the-science reviewInternational Journal Of Impotence Research, 2002
- Impact of Symptoms of Prostatism on Level of Bother and Quality of Life of Men in the French CommunityJournal of Urology, 1995
- ‘Prostate‐related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptomsBritish Journal of Urology, 1994